RT Journal Article
SR Electronic
T1 Publication bias in pharmacogenetics of statin-associated muscle symptoms, an umbrella review with a meta-epidemiological study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.06.24303892
DO 10.1101/2024.03.06.24303892
A1 Gougeon, A
A1 Aribi, I
A1 Guernouche, S
A1 Lega, JC
A1 Wright, JM
A1 Verstuyft, C
A1 Lajoinie, A
A1 Gueyffier, F
A1 Grenet, G
YR 2024
UL http://medrxiv.org/content/early/2024/03/08/2024.03.06.24303892.abstract
AB Background Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Adjusting statin dosages for solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype has been proposed to reduce SAMS. We hypothesized that the association between SLCO1B1 genotype and SAMS is misestimated because of publication bias.Methods We searched for published systematic reviews evaluating the association between SLCO1B1 genotype and SAMS. We collected the odds ratio (OR) of this association in each clinical study. We assessed the presence of publication bias using the visual inspection of a funnel plot and Egger’s test and used the Bayes Factor (BFPublication-bias) of the Robust Bayesian Meta-Analysis (RoBMA) as a sensitivity analysis. We evaluated the effect of publication bias by comparing qualitatively and quantitatively (ratio of OR [ROR]) OR of the meta-analysis i) uncorrected for potential publication bias (ORUncorrected) and ii) corrected using the trim-and-fill (ORTrim&Fill). We also used the RoBMA (ORRoBMA) for corrected OR as a sensitivity analysis. Our primary analysis covered the associations between any SLCO1B1 genotype and any statin drug. Secondary analysis focused on SLCO1B1 genotypes and statin drug subgroups.Results We included 8 cohort and 11 case-control studies, totaling 62 OR of three SLCO1B1 genotypes and five statin drugs plus one ‘mixed’ statin treatment. All controls were statin-tolerant patients. In the primary analysis, the funnel plot was suggestive of publication bias, confirmed by Egger’s test (p=0.001) and RoBMA (BFPublication-bias=18). Correcting the estimate for publication bias resulted in loss of the association, from a significant ORUncorrected (1.31 95% CI [1.13– 1.53]) to corrected ORs suggesting no difference: i) ORTrim&Fill (1.07 95% CI [0.89–1.30]) and ii) ORRoBMA (1.02 95% CI [1.00–1.33]). The RORTrim&Fill and the RORRoBMA suggested that publication bias overestimated the association by 18% and 23%, respectively. The results were similar for the most studied SLCO1B1 genotype, as for simvastatin and atorvastatin.Conclusion The effect of the SLCO1B1 genotype on the risk of developing SAMS is overestimated in the published literature. This could lead prescribers to incorrectly decreasing statin doses or even avoiding statin use, leading to a loss of the potential cardiovascular benefit of statins.Clinical perspective What is new? There is significant publication bias in the available literature regarding the association between SLCO1B1 genotype and statin-associated muscle symptoms.The available literature overestimates the importance of the SLCO1B1 genotype on statin-associated muscle symptoms. What are the clinical implications? The cardiovascular benefit of statins might be wrongly lost when adjusting statin therapy with the SLCO1B1 genotype.The effect of publication bias should be considered when writing guidelines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Arthur Gougeon's CIFRE PhD grant between RCTs, Lyon, France and the Laboratoire de Biométrie et Biologie Evolutive UMR CNRS 5558, Université Lyon 1. No external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe protocol was registered a priori on the Open Science Framework https://osf.io/36jq8/